Management of post-transplant Epstein-Barr virus-related lymphoproliferative disease in solid organ and hematopoietic stem cell recipients

Revista da Sociedade Brasileira de Medicina Tropical

Maluf, Natalya Zaidan¹  Pierrotti, Lígia Camera¹  Aquino, Maria Zilda de¹  Caiaffa-Filho, Hélio Helh¹  Lopes, Marta Heloisa¹  Marques, Heloisa Helena de Sousa¹  Campos, Silvia Vidal¹  Shikanai-Yasuda, Maria Aparecida¹  Costa, Silvia Figueiredo¹  Azevedo, Luiz Sérgio Fonseca de¹  Universidade de São Paulo, São Paulo¹ 

关键词: Epstein-Barr virus;    Lymphoproliferative disorders;    Transplantation;    Diagnosis;    Combined modality therapy;   

DOI  :  10.1590/0037-8682-0036-2014

学科分类：农业科学（综合）

来源: Sociedade Brasileira de Medicina Tropical

【 摘 要 】

Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) is one of the most serious complications associated with solid organ and hematopoietic stem cell transplantation. PTLD is most frequently seen with primary EBV infection post-transplant, a common scenario for pediatric solid organ recipients. Risk factors for infection or reactivation of EBV following solid organ transplant are stronger immunosuppressive therapy regimens, and being seronegative for receptor. For hematopoietic stem cell transplantation, the risk factors relate to the type of transplant, human leukocyte antigen disparity, the use of stronger immunosuppressants, T-cell depletion, and severe graft-versus-host disease. Mortality is high, and most frequent in patients who develop PTLD in the first six months post-transplant. The primary goal of this article is to provide an overview of the clinical manifestations, diagnosis, accepted therapies, and management of EBV infection in transplant recipients, and to suggest that the adoption of monitoring protocols could contribute to a reduction in related complications.Key words: Epstein-Barr virus; Lymphoproliferative disorders; Transplantation; Diagnosis; Combined modality therapy

【 授权许可】

Unknown